Afimmune receives a patent allowance for Oral AF102 in the US

Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis
March 29, 2017
Show all

Afimmune receives a patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th October 2017 – Afimmune (AF), a privately held drug discovery and development company, today announced receipt of allowance for a patent application in the United States of America (US). The allowance protects oral compositions of the Company’s lead compound AF102 (15-HEPE).

The United States Patent and Trademark Office (USPTO) has allowed the US patent application entitled “Compositions comprising 15-HEPE and methods of using the same”, which has the serial number 15/383,889. This will provide exclusivity for oral compositions of AF102 until 2036 in the US where the Company has received Fast Track Designation from the Food and Drug Administration (FDA).

Mr. Tien Nghiem, Director of Product Development and Intellectual Property at AF, commented: “We are delighted to have received a Notice of Allowance from the USPTO for compositions of AF102. This additional patent strengthens the Company’s exclusivity position. Afimmune continues to prosecute other AF102 patent families in the US and other key jurisdictions.”

Afimmune has a Phase 2 trial ongoing exploring the therapeutic effect of AF102 in patients with non-alcoholic fatty liver disease (NAFLD) and plans to start a separate Phase 2 trial in patients with chronic obstructive pulmonary disease (COPD) soon. Both trials are expected to read out towards the end of 2018.

About Afimmune
Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on inflammatory conditions of the human primary organs including the liver and the lung. AF102 (previously designated DS102) was spun out by DS Biopharma into Afimmune in 2016.

Contact:
Afimmune: info@afimmune.com